$treet Trader Lion's Den

[BottomBounce]

$BNGO The first study of this kind is underway in Wuhan, China, and is being performed at the site of Wuhan-based GrandOmics, a service provider using Bionano technology. Now, the Hannover Medical School is launching a study involving 1,000 patients and controls, consisting of COVID-19 patients and their partners and first-degree relatives as controls. Partners have typically been intensely exposed to the same strain of the virus as the patients, and differences in disease severity can be caused by genetic variation. The participants will have their genomes analyzed using Next-Generation Sequencing (NGS), and Bionano Genome Imaging. Additionally, the study participants will undergo analysis of their transcriptome to look at gene expression, their metabolome, and a variety of immune markers such as cytokines and T-cell response. The goal of the study is to identify genomic variants that affect the disease, and immune or metabolic variables in the healthier participants that can protect against more severe disease, and to use this knowledge for the development of novel therapies and vaccines. https://www.barchart.com/story/stocks/quotes/BNGO/overview/4628110/bionano-genomics-to-support-largest-study-to-date-on-covid-19-disease-susceptibility